Parallax Volatility Advisers
AUPH icon

Parallax Volatility Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Parallax Volatility Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,000
Closed -$166K – 2011
2024
Q2 		$166K Buy
29,000
+26,000
+867% +$137K ﹤0.01% 1631
2024
Q1 		$15K Buy
+3,000
New +$20.4K ﹤0.01% 1681
2023
Q3 		– Sell
-600
Closed -$5.81K – 2275
2023
Q2 		$5.81K Buy
+600
New +$6.23K ﹤0.01% 2216
2017
Q4 		– Sell
-50,000
Closed -$314K – 3944
2017
Q3 		$314K Hold
50,000
– – ﹤0.01% 1360
2017
Q2 		$307K Sell
50,000
-84,400
-63% -$569K ﹤0.01% 1348
2017
Q1 		$987K Sell
134,400
-20,400
-13% -$94.2K ﹤0.01% 1163
2016
Q4 		$325K Buy
+154,800
New +$498K ﹤0.01% 1680

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallax Volatility Advisers's AUPH Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 49,279 shares — an estimated $396K sold.

Parallax Volatility Advisers first reported a position in AUPH in Q4 2016 and held it in 17 quarters. The position peaked at $2.51M in Q1 2022. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 49,279 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $396K.
  • Parallax Volatility Advisers first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 17 quarters.
  • Parallax Volatility Advisers's Aurinia Pharmaceuticals position peaked at $2.51M in Q1 2022.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.